Review
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Nov 14, 2013; 19(42): 7327-7340
Published online Nov 14, 2013. doi: 10.3748/wjg.v19.i42.7327
Hepatobiliary manifestations in inflammatory bowel disease: The gut, the drugs and the liver
María Rojas-Feria, Manuel Castro, Emilio Suárez, Javier Ampuero, Manuel Romero-Gómez
María Rojas-Feria, Manuel Castro, Emilio Suárez, Javier Ampuero, Manuel Romero-Gómez, Unit for Medical and Surgical Management of Digestive Diseases and CIBERehd, Valme University Hospital, University of Seville, E-41014 Sevilla, Spain
Author contributions: Romero-Gómez M designed the concept for this review and contributed to the writing and reviewing of the final revision of the manuscript; Rojas-Feria M, Castro M, Ampuero J, and Suárez E contributed to the study design, literature search, manuscript writing, and final revision of the article; all authors approved the final version of the manuscript.
Correspondence to: Manuel Romero-Gómez, MD, PhD, Professor of Medicine, Unit for Medical and Surgical Management of Digestive Diseases and CIBERehd, Valme University Hospital, University of Seville, Avda. Bellavista s/n, E-41014 Sevilla, Spain. mromerogomez@us.es
Telephone: +34-95-5015761 Fax: +34-95-5015899
Received: June 27, 2013
Revised: September 23, 2013
Accepted: September 29, 2013
Published online: November 14, 2013
Processing time: 144 Days and 8.9 Hours
Core Tip

Core tip: Hepatobiliary disorders are common extraintestinal manifestations of inflammatory bowel disease (IBD) that become a diagnostic challenge for the gastroenterologist. In this review, we have summarized the main diseases involving the hepatobiliary system in IBD and secondary liver toxicity to IBD treatment. This review also highlights the impact of immunosuppressive and anti-tumor necrosis factor treatment in hepatitis B and C, as well as its prophylaxis and treatment, according to current clinical practice guidelines.